CLINICAL TRIALS PROFILE FOR LEUPROLIDE MESYLATE
✉ Email this page to a colleague
All Clinical Trials for leuprolide mesylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00500110 ↗ | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | Completed | Novartis Pharmaceuticals | Phase 2 | 2003-06-01 | Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway. |
| NCT00500110 ↗ | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | Completed | M.D. Anderson Cancer Center | Phase 2 | 2003-06-01 | Primary Objective: 1. To evaluate the pathological complete response rate to neoadjuvant hormonal ablation, Imatinib and Docetaxel (HID) in high-risk localized prostate cancer. Secondary Objectives: 1. To describe the time to prostate specific antigen (PSA)-progression after neoadjuvant HID and radical prostatectomy in high-risk localized prostate cancer. 2. To correlate pathological response with modulation of the Platelet-Derived Growth Factor Receptor (PDGFR) pathway. |
| NCT02234115 ↗ | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | Completed | QPS-Qualitix | Phase 3 | 2014-08-01 | The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart. |
| NCT02234115 ↗ | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | Completed | Foresee Pharmaceuticals Co., Ltd. | Phase 3 | 2014-08-01 | The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart. |
| NCT02712320 ↗ | Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg | Completed | QPS-Qualitix | Phase 3 | 2016-02-01 | This is a safety extension of up to 12 months of additional treatment with LMIS 50 mg after the subject has completed 12 months of treatment under Protocol FP01C-13-001 and remain eligible for continued treatment with androgen deprivation therapy. Subjects participating in Protocol FP01C-13-001-EX will be followed for safety only. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for leuprolide mesylate
Condition Name
Clinical Trial Locations for leuprolide mesylate
Trials by Country
Clinical Trial Progress for leuprolide mesylate
Clinical Trial Phase
Clinical Trial Sponsors for leuprolide mesylate
Sponsor Name
